User:Mr. Ibrahem/Pyoderma gangrenosum
| Pyoderma gangrenosum | |
|---|---|
 | |
| Pyoderma gangrenosum on the leg of a person with ulcerative colitis. | |
| Specialty | Dermatology |
| Symptoms | A small bump that expands into a painful ulcer and progressively grows[1][2] |
| Usual onset | 20s to 50s[1] |
| Duration | Months[2] |
| Causes | Unknown[1] |
| Risk factors | Autoimmune disorders, cancer[3] |
| Diagnostic method | Based on symptoms after ruling out other causes[3] |
| Differential diagnosis | Pyogenic granuloma, Sweet syndrome, sporotrichosis[3][1] |
| Treatment | Corticosteroids, ciclosporin, infliximab, canakinumab[4] |
| Frequency | 1 in 100,000 per year[1] |
Pyoderma gangrenosum (PG) is a skin disease which generally begins as a small bump that expands into an ulcer which progressively grows.[1] The ulcers have well defined borders and are often painful.[1] While the legs are often affected, lesions may form anywhere.[1] It may begin in the area of a minor injury.[2]
The cause is unknown, though believed to be autoinflammatory.[1][2] It may be associated with autoimmune disorders such as rheumatoid arthritis or inflammatory bowel disease (IBD), cancer including leukemia, and certain drugs and medications.[3][2] It is not infectious.[3] Diagnosis is based on symptoms after ruling out other possible causes.[3]
Treatments may include corticosteroids, ciclosporin, infliximab, or canakinumab.[4] Once healing has begun, skin grafting may be carried out.[2] Without treatment the ulcers may grow, stabilize, or gradually heal.[2] Despite treatment healing may take months and a scar may remain.[2]
About 1 per 100,000 people are newly affected per year in the United States.[1] Among those with IBD, about 2% are affected.[2] Women are more commonly affected than men.[1] Those between 20 to 50 years of age are most commonly affected.[1] The disease was first identified in 1930.[5]
References[edit]
- ^ a b c d e f g h i j k l "Pyoderma Gangrenosum". NORD (National Organization for Rare Disorders). Archived from the original on 22 January 2021. Retrieved 14 May 2021.
- ^ a b c d e f g h i "Pyoderma gangrenosum". dermnetnz.org. DermNet NZ. Archived from the original on 11 April 2021. Retrieved 14 May 2021.
- ^ a b c d e f Schmieder, SJ; Krishnamurthy, K (January 2021). "Pyoderma Gangrenosum". PMID 29489279.
{{cite journal}}: Cite journal requires|journal=(help) - ^ a b Partridge AC, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P (August 2018). "Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials". The British Journal of Dermatology. 179 (2): 290–295. doi:10.1111/bjd.16485. PMID 29478243. S2CID 3504429.
- ^ Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G (September 2009). "Pyoderma gangrenosum: an updated review". Journal of the European Academy of Dermatology and Venereology. 23 (9): 1008–17. doi:10.1111/j.1468-3083.2009.03199.x. PMID 19470075. S2CID 29773727.